Call Now

A375-hNIS-Neo/eGFP-Puro

Species: Human

Cell type: Melanoma

Transgenes: Human sodium iodide symporter (hNIS) with neomycin resistance (Neo) for selection with G418 and enhanced green fluorescent protein (eGFP) with puromycin resistance for selection with puromycin

Media: DMEM, 10% FBS, 1% Pen/Strep, 0.6 mg/mL G418, 1 μg/mL puromycin

Description: A375-hNIS-Neo/eGFP-Puro is a polyclonal population of the human malignant melanoma cell line A375 (ATCC® CRL-1619™) transduced with LV-hNIS-IRES-Neo (LV013) encoding the human sodium iodide symporter (hNIS) cDNA under the spleen focus-forming virus (SFFV) promoter linked to the neomycin resistance gene (Neo) via an internal ribosomal entry site (IRES) and LV-eGFP-PGK-Puro (LV031) encoding the enhanced green fluorescent protein (eGFP) cDNA under the spleen focus-forming virus (SFFV) promoter and the puromycin resistance gene (Puro) under the mouse phosphoglycerate kinase (PGK) promoter.

The lentiviral vector used is a self-inactivating (SIN) vector in which the viral enhancer and promoter has been deleted. Transcription inactivation of the LTR in the SIN provirus increases biosafety by preventing mobilization by replication competent viruses and enables regulated expression of the genes from the internal promoters without cis-acting effects of the LTR (Miyoshi et al., J Virol. 1998).

Mycoplasma Testing: The A375-hNIS-Neo/eGFP-Puro cell line has been tested for mycoplasma contamination and is certified mycoplasma free.

Cell Line Authentication: The parental A375 cell line was authenticated are certified free of interspecies cross-contamination by short tandem repeat (STR) profiling with 9 STR loci including CSF1PO, D13S317, D16S539, D5S818, D7S820, TH01, TPOX, vWA and sex chromosome marker Amelogenin.

Recommended uses:

In vitro: This is a high hNIS/eGFP expressing cell line suitable for use as a positive control cell line in iodine uptake and fluorescence assays to verify NIS or GFP expression respectively in your lentiviral transduced cells.

In vivo: A375 cells form tumors post implantation into immunosuppressed mice. The in vivo growth of these tumors can be monitored using noninvasive, high-resolution 3D PET/SPECT imaging or optical imaging for GFP.

Publications that used associated reagents: 

LV-eGFP-PGK-Puro (LV031): Shen et al. Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia. Blood. 2016. March 17: 127(11): 1449-58

References on NIS imaging:

1. Fruthwirth et al. A whole body dual modality radionuclide optical strategy for preclinical imaging of metastasis and heterogeneous treatment responses in different. microenvironments. J. Nucl. Med 2014. 55(4): 686-94.

2. Penheiter et al. The sodium iodide symporter (NIS) as an imaging reporter for gene, viral and cell-based therapies. Curr Gene Ther. 2012, 12(1):33-47.

Cell photos: Low- and high-density cell morphology (200X)

NIS Function Assay (Iodine Uptake): Cells were incubated with 125I for 1h in the presence or absence of KClO4, an inhibitor of iodine uptake. Radioiodine concentrated within the cells was measured with a gamma counter.

 

Flow Cytometry for eGFP: A375-hNIS-Neo/eGFP-Puro (green) or isotype control (A375-Fluc-Puro; grey) cells were fixed with paraformaldehyde and analyzed by flow cytometry (20,000 events).

Why Choose Imanis?

With quality reagents, services, and support, we have you covered at all stages of your study. Our expert scientists can help you select the best reagents for your needs and offer tips to optimize your experiments and achieve superior results. Our wide-range of reporter gene and oncolytic virus reagents undergo rigorous quality control testing so you can be confident in the quality of the products you receive. And with our competitive prices, you can complete your study for less.

  • “Our group has, and continues to, use NIS as a noninvasive reporter for cell transplantation studies in mice and in pigs. Imanis has provided expert technical and analytical support for this research, and has allowed us to publish our research in high impact journals, including Science Translational Medicine.” – Dr. Raymond Hickey, Mayo Clinic

Use Fewer Animals

Our Reduction Campaign

At Imanis, we are committed to promoting the practice of the 3Rs in animal research. Learn how we are decreasing the use of animals and research as well as saving up to 15% on your orders. Continue reading...

Use Fewer Animals

Our Reduction Campaign

At Imanis, we are committed to promoting the practice of the 3Rs in animal research. Learn how we are decreasing the use of animals and research as well as saving up to 15% on your orders. Continue reading...